Phase 1 N=6 Trial of ARV-110 and Abiraterone in Participants With Metastatic Prostate Cancer
Prostate Cancer Metastatic
Primary: Safety Lead-in: Number of Participants Experiencing Dose Limiting Toxicities (DLTs) — 0 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=60 Intervention to Improve Diabetes Outcomes in Older African American Women With Multi-Caregiving Burden
Type 2 Diabetes
Primary: Mean Change in HbA1c% From Baseline to 6 Months — 0.57; 0.53 Mean Change in HbA1c%
N/A N=12 Penguin Cold Caps in the Prevention of Hair Loss in Breast Cancer Patients
Breast Cancer
Primary: Efficacy of PenguinTM Cold-caps for Prevention or Reduction of CIA — 4; 3; 3 Participants
Phase 1 N=16 Study of the BIOPIN 6 Naltrexone Implant in Healthy Adults
Opioid Use Disorder
Primary: Naltrexone Plasma Concentration Area Under the Curve (AUC₀-Day 98) — 11,556; 20,817; NA ng·hr/mL
Phase 2 N=54 Clinical Trial to Assess Efficacy and Safety of the Human Anti-CD38 Antibody Felzartamab (MOR202) in IgA Nephropathy
Immunoglobulin A (IgA) Nephropathy
Primary: Part 1: Relative Change From Baseline in Urine Protein to Creatinine Ratio (UPCR) in 24-hour Urine at Month 9 — -24.7; -16.5; -30.6; -38.5 gram per gram (g/g) — p=0.6837
Phase 2 N=78 A Study to Investigate the Efficacy and Safety of NT 201 (Botulinum Toxin) Compared With Placebo for the Treatment of Adult Participants With Essential Tremor in the Arm
Essential Tremor of the Upper Limb
Primary: Unilateral Treatment Period: Change From Baseline to Week 6 in Maximum Tremor Amplitude of the Wrist — -0.25; -0.46 degrees of arc
N/A N=41 TetricCAD Crown Clinical Study
Fractured Tooth · Decayed Tooth · Unsatisfactory Restoration of Tooth
Primary: Crown Failure — 4 crowns
Phase 2 N=4 Neuromodulation Techniques After SCI
Spinal Cord Injury
Primary: 10-meter Walking Speed (m/Sec) — 0.165; 0.215; 0.13; 0.13 speed (m/sec)
N/A N=19 Effects of Exercise Training and Ketone Ester on Muscle Strength and Cardiovascular Response in Parkinson's Disease
Parkinson Disease
Primary: Change in Duration of 80 Rpm Endurance Test — 26.31; 25.84; 15.62; 12.12 minutes
N/A N=176 LINK-HF2 - Remote Monitoring Analytics in Heart Failure
Heart Failure
Primary: Heart Failure Hospitalization Rate — 13; 16 Heart failure hospitalizations
Phase 3 N=100 Study to Assess the Safety, Pharmacokinetics, and Efficacy of Baloxavir Marboxil in Chinese Pediatric Participants 1 to <12 Years of Age With Influenza Symptoms
Influenza
Primary: Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs) — 24; 12; 2; 0 Participants
N/A N=206 Improving Cardiac Rehabilitation Outcomes Through Mobile Case Management (iCARE)
Acute Myocardial Infarction · Acute Coronary Syndrome · Stable Angina Pectoris
Primary: Change in Metabolic Equivalents of Task (METS) — 6.48; 7.40; 7.43 mL/kg/min
Phase 2 N=10 Treatment of Restless Leg Syndrome (RLS) Augmentation With Ecopipam, a D1 Specific Antagonist
Restless Legs Syndrome · Augmentation
Primary: Change From Baseline (Predose) in Mean International Restless Legs Syndrome (IRLS) Rating Scale at End of Intervention Period — 20.6; 21.6; 16; 18.8 score on a scale
N/A N=131 Crossing the Divide: Piloting Integrated Care to Reduce Amputations Among Rural Patients With Diabetic Foot Ulcers
Diabetic Foot · Diabetic Ulcer of Left Foot · Diabetic Ulcer of Right Foot
Primary: Proportion of Patients Receiving Guideline-concordant Vascular and Infectious Disease Care Processes — 14; 6 Participants
Phase 4 N=50 Septorhinoplasty Post-operative Pain Control With SPG Nerve Block
Deviated Nasal Septum
Primary: Post Operative Pain Scores — 3.9; 3.8; 2.7; 2.9 pain score on a scale of 0-10